Aralez Pharmaceuticals Inc. 4

4 · Aralez Pharmaceuticals Inc. · Filed Nov 30, 2016

Form 4

Period: 2016-11-28

Director

Transactions

Sale
Common Shares, without par value
2016-11-28$4.65/sh−20,000$93,000→ 594,094 total
Exercise/Conversion
Common Shares, without par value
2016-11-29$3.92/sh+104,778$410,730→ 698,872 total
Sale
Common Shares, without par value
2016-11-29$4.99/sh−104,778$523,146→ 594,094 total
Exercise/Conversion
Employee Stock Option (right to buy)
2016-11-28−20,000→ 104,778 total
Exercise: $3.92Exp: 2016-12-01→ Common Shares, without par value (20,000 underlying)
Exercise/Conversion
Common Shares, without par value
2016-11-28$3.92/sh+20,000$78,400→ 614,094 total
Exercise/Conversion
Employee Stock Option (right to buy)
2016-11-29−104,778→ 0 total
Exercise: $3.92Exp: 2016-12-01→ Common Shares, without par value (104,778 underlying)

Holdings

Footnotes (6)

[F1]Price is presented in Canadian dollars.
[F2]The exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2016, as amended.
[F3]Price is presented in United States dollars.
[F4]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 16, 2016, as amended.
[F5]This transaction was executed in multiple trades at prices ranging from $4.76 to $5.10. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F6]The option was exercisable as of the Reporting Person's previous filing on Form 3, dated as of February 8, 2016.

Documents

1 file